Nipocalimab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | FcRn |
| Clinical data | |
| Trade names | Imaavy |
| Other names | nipocalimab-aahu |
| License data |
|
| Routes of administration | Intravenous infusion |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6266H9722N1670O1992S46 |
| Molar mass | 141797.16 g·mol−1 |
Nipocalimab, sold under the brand name Imaavy, is a monoclonal antibody used for the treatment of generalized myasthenia gravis. It is a neonatal Fc receptor blocker. It is an high affinity, fully human, aglycosylated, effectorless immunoglobulin G (IgG) anti-FcRn monoclonal antibody.
Nipocalimab was approved for medical use in the United States in April 2025.